Abstract
e21598Background: Nivolumab was the first anti-PD1 therapy to receive a European marketed authorization for the treatment of advanced (unresectable or metastatic) melanoma. To collect and evaluate ...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have